PubMed Health treatment related to Macular Degeneration, Age-Related, 1: 63
There is currently no effective treatment for dry macular degeneration . Wet AMD is typically treated with medicine that is injected into the eye to prevent blood vessel growth. This medicine is known as anti-vascular endothelial growth factor (anti-VEGF). Although this treatment can’t cure AMD, it can stop or at least slow down the progression. Sometimes vision even improves again during treatment. Photodynamic therapy is less effective, and therefore no longer that common. Laser therapy is also only rarely used nowadays. This treatment involves heating and destroying abnormal blood vessels with laser beams. Photodynamic therapy applies a combination of medication and laser beams. Both of these therapies are only very rarely suitable for treating wet AMD. They also have more side effects than anti-VEGF therapy. In some exceptional cases – and if no other treatment has helped – abnormal blood vessels may be removed surgically. Dietary supplements containing a combination of certain ingredients (vitamin C, vitamin E , zinc , copper, and lutein with zeaxanthin or beta-carotene ) may be able to slow the progression of the disease in people who are at greater risk of developing late-stage AMD.
Drugs for Macular Degeneration, Age-Related, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 311)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Nepafenac |
Approved, Investigational |
Phase 4 |
|
78281-72-8 |
151075 |
Synonyms:
2-Amino-3-benzoylbenzeneacetamide
AHR 9434
AHR-9434
AL 6515
AL-6515
Amfenac amide
|
ILEVRO
Nepafenac
Népafénac
Nepafenaco
Nepafenacum
Nevanac
|
|
2 |
|
Ketorolac |
Approved |
Phase 4 |
|
74103-06-3, 66635-83-4 |
3826 |
Synonyms:
(+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylate
(+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
(+-)-Ketorolac
ACULAR
Acular LS
Acular Preservative Free
Acular®|Toradol®
Ketoralac
Ketorolac
|
Kétorolac
Ketorolac tromethamine
Ketorolaco
Ketorolaco [Spanish]
Ketorolacum
Ketorolacum [Latin]
rac-Ketorolac
Toradol
|
|
3 |
|
Lactitol |
Approved, Investigational |
Phase 4 |
|
585-86-4 |
157355 |
Synonyms:
4-O-beta-D-Galactopyranosyl-D-glucitol
4-O-β-D-Galactopyranosyl-D-glucitol
D-Lactitol
Emportal
Importal
Lactitol
|
Lactitolum
Neda lactiv importal
Oponaf
Pizensy
WURCS=2.0/2,2,1/[H2122H][a2112h-1b_1-5]/1-2/a4-b1
|
|
4 |
|
Lidocaine |
Approved, Vet_approved |
Phase 4 |
|
137-58-6 |
3676 |
Synonyms:
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
a-Diethylamino-2,6-dimethylacetanilide
ALGRX 3268
ALGRX-3268
ALPHACAINE
alpha-Diethylamino-2,6-dimethylacetanilide
ANESTACON
Astrazeneca brand OF lidocaine
Dalcaine
Dentipatch
Dilocaine
EMBOLEX
IONTOCAINE
Jenapharm brand OF lidocanine hydrochloride
L-Caine
Lidocaina
Lidocaína
LIDOCAINE
Lidocaine carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
|
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
LIDOCATON
Lidoderm
LIDOPEN
Lignocaine
LIGNOCAINE HCL
LIGNOSTAB
LMX 4
Novocol brand OF lidocaine hydrochloride
NSC-40030
Octocaine
ORAQIX
Strathmann brand OF lidocaine hydrochloride
VAGISIL
Xylesthesin
Xylocaine
Xylocaine®
Xylocitin
XYLODASE
Xyloneural
XYLOTOX
ZTLIDO
Α-diethylamino-2,6-dimethylacetanilide
|
|
5 |
|
Indomethacin |
Approved, Investigational |
Phase 4 |
|
53-86-1 |
3715 |
Synonyms:
{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetate
{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid
1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetate
1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid
Aconip
Amuno
Apo-Indomethacin
Argun
Arthrexin
ARTRACIN
ARTRACIN SR
Artrinovo
Artrivia
BERLIND 75 RET
Bonidin
Bonidon
Bonidon Gel
Catlep
Chibro-Amuno
Chrono-Indicid
Chrono-Indocid
Confortid
Dolcidium
Dolcidium Pl
Dolovin
Durametacin
Elmetacin
Flexin Continus
FLEXIN-25 CONTINUS
FLEXIN-50 CONTINUS
FLEXIN-75 CONTINUS
Hicin
Hydrochloride, indomethacin
Idomethine
IMBRILON
IMN
Inacid
Indacin
Indaflex
Indameth
Indmethacine
Indocid
Indocid Pda
INDOCID RET
Indocid Sr
Indocid®|Indocin®
INDOCID-R
Indocin
Indocin I.V
Indocin I.V.
INDOCIN SR
INDODERM
INDOFLEX
INDOLAR
INDOLAR SR
INDO-LEMMON
INDOMAX-25
INDOMAX-75 SR
Indomecol
|
Indomed
Indomee
Indomet 140
Indometacin
INDOMETACIN FARNESIL
Indometacina
Indometacine
Indometacinum
Indometacyna
INDOMETHACIN
Indomethacin hydrochloride
Indomethacine
Indomethacinum
Indomethancin
Indomethazine
Indomethegan
Indomethine
Indometicina
Indomo
INDOMOD
INDO-PAED
Indo-Phlogont
Indoptic
INDOPTOL
Indo-Rectolmin
Indorektal
Indo-Spray
Indo-Tablinen
INDOTARD MR 75
Indoxen
Inflazon
Infrocin
Inteban Sp
Lausit
LEDMECIN
Liometacen
MAXIMET SR
Metacen
Metartril
Methazine
Metindol
Miametan
Mikametan
MOBILAN
Novomethacin
Novo-Methacin
NSC-77541
Nu-Indo
Osmosin
PARDELPRIN MR
Reumacide
Rhemacin La
RHEUMACIN LA
RIMACID
Sadoreum
SLO-INDO
Tannex
TIVORBEX
Vonum
|
|
6 |
|
Temazepam |
Approved, Investigational |
Phase 4 |
|
846-50-4 |
5391 |
Synonyms:
3 Hydroxydiazepam
3-Hydroxydiazepam
AHP brand OF temazepam
Alphapharm brand OF temazepam
apo Temazepam
apo-Temazepam
Apotex brand OF temazepam
CT Arzneimittel brand OF temazepam
CT-Arzneimittel brand OF temazepam
Dasuen
Desitin brand OF temazepam
Euhypnos
Gen temazepam
Genopharm brand OF temazepam
Genpharm brand OF temazepam
Gen-temazepam
Hydroxydiazepam
ICN brand OF temazepam
Katwijk brand OF temazepam
KENTEPAM
Knoll brand OF temazepam
Levanxol
Mallinckrodt brand OF temazepam
Methyloxazepam
N-Methyloxazepam
Nocturne
Norkotral tema
Normison
Normitab
Nortem
Norton brand OF temazepam
Novartis brand OF temazepam
novo Temazepam
Novopharm brand OF temazepam
|
novo-Temazepam
NSC-246303
Nu pharm brand OF temazepam
Nu temazepam
Nu-pharm brand OF temazepam
Nu-temazepam
Orion brand OF temazepam
Oxydiazepam
Pfizer brand 1 OF temazepam
Pfizer brand 2 OF temazepam
Pharmascience brand OF temazepam
Planum
PMS Temazepam
PMS-Temazepam
Pronervon T
Remestan
RER603
Restoril
RESTORIL (TN)
Scheffler brand OF temazepam
Sigma brand OF temazepam
Signopam
Tema, norkotral
TEMAZ
Temaze
Temazep von CT
Temazepam
TEMAZEPAM CIV
Temtabs
Tenox
Von CT, temazep
WY-3917
Wyeth brand OF temazepam
|
|
7 |
|
Povidone-iodine |
Approved |
Phase 4 |
|
25655-41-8 |
|
Synonyms:
Iodopovidone
Povidone iodine
Povidone, iodinated
|
|
|
8 |
|
Iodine |
Approved, Investigational |
Phase 4 |
|
7553-56-2 |
807 |
Synonyms:
Cadex
Diiodine
I2
Iode
Iodine
Iodine 127
Iodine-127
Iodine-molecule
|
Iodio
iodo
Iodum
Jod
Jood
Molecular iodine
NSC-42355
Tincture iodine
|
|
9 |
|
Povidone K30 |
Approved, Experimental, Withdrawn |
Phase 4 |
|
9003-39-8 |
6917 131751496 |
Synonyms:
1-Ethenyl-2-pyrrolidinone
1-Ethenyl-2-pyrrolidinone (9ci)
1-Ethenyl-2-pyrrolidinone homopolymer
1-Ethenyl-2-pyrrolidinone homopolymer, 9ci
1-Ethenyl-2-pyrrolidinone polymers
1-Ethenyl-2-pyrrolidinone, homopolymer
1-Vinyl-2-pyrrolidinone
1-Vinyl-2-pyrrolidinone cross-linked insoluble polymer
1-Vinyl-2-pyrrolidinone homopolymer
1-Vinyl-2-pyrrolidinone polymer
1-Vinyl-2-pyrrolidinone, monomer
1-Vinyl-2-pyrrolidinone, polymer
1-Vinyl-2-pyrrolidone
1-Vinyl-2-pyrrolidone polymer
1-Vinylpyrrolidin-2-one
1-vinylpyrrolidin-2-one homopolymer
1-Vinylpyrrolidinone
1-Vinylpyrrolidone
2-Pyrrolidinone, 1-ethenyl, homopolymer
2-Pyrrolidinone, 1-ethenyl-, homopolymer
2-Pyrrolidinone, 1-vinyl-, polymers
Agent at 717
Agent at-717
Agrimer
Albigen a
Aldacol Q
Alphadine
Alphadines
Antaron P 804
Arufil
Betadine
Betadines
Betaisodona
Betaisodonas
Bolinan
Bolinan 40
Crospovidone
Disadine
Disadines
Dulcilarme
Dulcilarmes
Duratears free
Enterode
Enterodes
Enterodez
Ganex P 804
Ganex P-804
Hemodesis
Hemodez
Huntington laboratories brand OF povidone iodine
Huntington laboratories brand OF povidone-iodine
Hypotear
Hypotears
Isodine
Isodines
K 115 (Polyamide)
K 25
K 25 (Polymer)
K 30
K 30 (Polymer)
K 60
K 60 (Polymer)
K115 (Polyamide)
K25 (Polymer)
K30 (Polymer)
K60 (Polymer)
Kollidin CLM
Kollidon
Kollidon 17
Kollidon 25
'Kollidon 25'
Kollidon 30
Kollidon CL
Lacophtal
Lacri-stulln
Lagrifilm
Liquifilm lagrimas
Luviskol
Luviskol K 30
Luviskol K 90
Luviskol K30
Luviskol K-30
Luviskol K90
N- Vinyl pyrrolidone
Neocompensan
Nutrivisc
N-Vinyl pyrrolidone
N-Vinyl-2-pyrrolidinone
N-Vinyl-2-pyrrolidone
N-Vinyl-2-pyrrolidone polymer
N-Vinylbutyrolactam polymer
N-Vinylpyrrolidinone
N-Vinylpyrrolidinone polymer
N-Vinylpyrrolidone
N-Vinylpyrrolidone polymer
N-Vinylpyrrolidone-2
Oculotect
Peragal ST
Peregal ST
Periston
Periston-N
Peviston
Pharmadine
Pharmadines
'plasdone'
Plasdone
Plasdone 4
Plasdone K 29-32
Plasdone K-26/28
Plasdone K29/32
Plasdone K29-32
|
Plasdone no. 4
Plasdone XL
Plasmosan
Polividone
Polvidone
Poly(1-(2-oxo-1-pyrrolidinyl)-1,2-ethanediyl)
Poly(1-(2-oxo-1-pyrrolidinyl)ethylene)
Poly(1-ethenyl-2-pyrrolidinone)
Poly(1-vinyl-2-pyrrolidinone)
Poly(1-vinyl-2-pyrrolidinone) homopolymer
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.1
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.2
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.3
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.4
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.5
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.6
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.7
Poly(1-vinyl-2-pyrrolidone)
Poly(1-vinylpyrrolidinone)
Poly(N-vinyl-2-pyrrolidinone)
Poly(N-vinyl-2-pyrrolidone)
Poly(N-vinylbutyrolactam)
Poly(N-vinylpyrrolidinone)
Poly(N-vinylpyrrolidone)
Poly(vinylpolypyrrolidone)
Poly(vinylpyrrolidinone)
Poly(vinylpyrrolidone)
Polyclar a. t
Polyclar a. t.
Polyclar at
Polyclar H
Polyclar L
Polyclar-at
Polygyl
Poly-N-vinyl pyrrolidone
Poly-N-vinylpyrrolidone
Polyplasdone
Polyplasdone XL
Polyvidon
Polyvidons
Polyvidonum
Polyvinyl pyrrolidone
Polyvinylpolypyrrolidone
Polyvinylpyrrolidone
Polyvinylpyrrolidone iodine
Polyvinylpyrrolidone iodines
Polyvinylpyrrolidone K 30
Polyvinylpyrrolidone K-29/32
Polyvinylpyrrolidone K30
Polyvinylpyrrolidone polymers
Polyvinylpyrrolidone, cross-linked
Povidona
Povidone
Povidone iodine
Povidone K29/32
Povidone K29-32
Povidone(usan)
Povidone, ban, usan
Povidone, unspecified
Povidone-iodine
Povidone-iodines
Povidonum
Protagen
Protagens
Protagent
Providine
Providines
PVP 1
PVP 2
PVP 3
PVP 4
PVP 40
PVP 5
PVP 6
PVP 7
PVP Iodine
PVP K 3
PVP K30
PVP K-30
PVP10_SIAL
PVP40_SIAL
PVP-I
PVP-Iodine
PVP-Iodines
PVP-K 15
PVP-K 3
PVP-K 30
PVP-K 60
PVP-K 90
PVPP
Refresh
Sauflon
Soothe
Subtosan
Tears plus
Tolpovidone I 131
Tolpovidone I-131
Toxobin
Unifluid
Unspecified povidone
Vidirakt S mit PVP
Vidisic PVP ophtiole
Vinisil
Vinyl-2-pyrrolidone
Vinylbutyrolactam
Vinylpyrrolidinone
Vinylpyrrolidinone polymer
Vinylpyrrolidone
Vinylpyrrolidone polymer
V-Pyrol
Wet-comod
|
|
10 |
|
Prednisolone phosphate |
Approved, Vet_approved |
Phase 4 |
|
302-25-0 |
|
Synonyms:
Prednisolone 21-(dihydrogen phosphate)
Prednisolone 21-monophosphate
|
Prednisolone 21-phosphate
|
|
11 |
|
Prednisolone acetate |
Approved, Vet_approved |
Phase 4 |
|
52-21-1 |
|
Synonyms:
ECONOPRED
FLO-PRED
METICORTELONE
NSC-10966
OMNIPRED
PRED FORTE
|
PRED FTE
PRED MILD
PREDNISOLONE 21-ACETATE
PREDNISOLONE ACETATE
STERANE
ULTRACORTENOL
|
|
12 |
|
Prednisolone |
Approved, Vet_approved |
Phase 4 |
|
50-24-8 |
4894 5755 |
Synonyms:
(11b)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11Β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione
1,4-Pregnadiene-11b,17a,21-triol-3,20-dione
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11b,17a,21-triol
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1,4-Pregnadiene-3,20-dione-11β,17α,21-triol
3,20-Dioxo-11b,17a,21-trihydroxy-1,4-pregnadiene
3,20-Dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene
3,20-Dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
Codelcortone
Co-Hydeltra
Cordrol
CORTALONE
Cotogesic
Cotolone
Decaprednil
Decortin H
DEKOTIL
Delcortol
Delta F
Delta(1)-Dehydrocortisol
Delta(1)-Dehydrohydrocortisone
Delta(1)-Hydrocortisone
DELTA.1-CORTISOL
DELTA.1-Cortisol|Orapred®|Pediapred®
Delta-Cortef
Deltacortenol
DELTACORTRIL
Deltacortril Enteric
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
Deltahydrocortisone
DELTALONE
Deltasolone
Delta-Stab
Deltisilone
Depo-Medrol
Derpo Pd
DESOWEN
Dexa-Cortidelt Hostacortin H
Di adreson F
Di-Adreson F
Di-adreson-F
DiAdresonF
Dicortol
DILACORT
Donisolone
Dydeltrone
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
FERNISOLONE-P
Flamasone
Hostacortin H
HYDELTRA
Hydeltrasol
HYDELTRA-TBA
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
IMS904
Inflamase Forte
Inflamase Mild
I-Pred
Key-Pred
Klismacort
Lentosone
Lite Pred
Medrol
|
Medrol Acetate
Metacortandralone
Methylprednisolone acetate
METICORTELONE
METI-DERM
Metreton
M-Predrol
NEO-DELTA-CORTEF
Nisolone
Nor-Pred T.B.A.
NSC-9120
NSC-9900
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
ORAPRED
Panafcortelone
Paracortol
Paracotol
PEDIAPRED
PEVANTI
POLY-PRED
PRDL
Precortalon
Precortancyl
Precortilon
PRECORTISYL
PRECORTISYL FTE
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
PRED-G
Predisolone sodium phosphate
PREDL
Predne-Dome
Prednelan
Prednicen
Predni-Dome
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone
Prednisolone acetate
Prednisolone sodium phosphate
Prednisolone tebutate
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
PRELONE
Prenolone
Rolisone
SCHERIPROCT
Scherisolon
SERVISONE
Solone
Steran
STERANE
Sterolone
Supercortisol
TRIDESILON
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
VERDESO
Δ(1)-dehydrocortisol
Δ(1)-dehydrohydrocortisone
Δ(1)-hydrocortisone
Δ-cortef
|
|
13 |
|
Methylprednisolone hemisuccinate |
Approved |
Phase 4 |
|
2921-57-5 |
1875 |
Synonyms:
Methylprednisolone hemisuccinate
Methylprednisolone hemisuccinic acid
|
Methylprednisolone hydrogen succinate
Methylprednisolone succinate
|
|
14 |
|
Methylprednisolone |
Approved, Vet_approved |
Phase 4 |
|
83-43-2 |
4159 6741 |
Synonyms:
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6Α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
1-Dehydro-6alpha-methylhydrocortisone
1-Dehydro-6a-methylhydrocortisone
1-Dehydro-6α-methylhydrocortisone
6 Methylprednisolone
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6a-Methyl-11b,17a,21-triol-1,4-pregnadiene-3,20-dione
6a-Methylprednisolone
6-Methylprednisolone
6Α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
6Α-methylprednisolone
Artisone-Wyeth
Besonia
Delta(1)-6alpha-Methylhydrocortisone
delta(1)-6a-Methylhydrocortisone
Dopomedrol
Esametone
Firmacort
J3.872E
Lemod
Medesone
Medixon
Medlone 21
Medrate
Medric acid
Medrol
Medrol Adt Pak
Medrol Dosepak
Medrol®|U-67590A
Medrone
Mesopren
|
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
Nirypan
Noretona
NSC-19987
Predni N Tablinen
Promacortine
Reactenol
Sieropresol
Solomet
SOLU-MEDROL
Summicort
Suprametil
U-67590A
Urbason
Urbasone
Wyacort
Δ(1)-6a-methylhydrocortisone
Δ(1)-6α-methylhydrocortisone
|
|
15 |
|
Cianidanol |
Approved, Withdrawn |
Phase 4 |
|
154-23-4 |
9064 |
Synonyms:
(-)-Epicatechin
(+)-(2R,3S)-5,7,3',4'-Tetrahydroxyflavan-3-ol
(+)-(2R:3S)-5,7,3',4'-Tetrahydroxyflavan-3-ol
(+)-(2R:3S)-5,7,3’,4’-Tetrahydroxyflavan-3-ol
(+)-3',4',5,7-Tetrahydroxy-2,3-trans-flavan-3-ol
(+)-3’,4’,5,7-Tetrahydroxy-2,3-trans-flavan-3-ol
(+)-Catechin
(+)-Catechin hydrate
(+)-Catechol
(+)-Cianidanol
(+)-Cyanidan-3-ol
(+)-Cyanidanol
(+)-Cyanidanol-3
(+/-)-catechin
(+/-)-catechin hydrate
(2R,3S)-(+)-Catechin
(2R,3S)-Catechin
(2R-trans)-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol
3,3',4',5,7-Flavanpentol
Acid, catechinic
Acid, catechuic
Biocatechin
CATECHIN
Catechinate
|
Catechinic acid
Catechuate
Catechuic acid
Catergen
Cianidanol
Cianidanolum
Cianidol
Cyanidanol
Cyanidanol 3
Cyanidanol-3
Cyanidol
D-(+)-Catechin
D-Catechin
D-Catechol
Dexcyanidanol
Epicatechin
KB 53
KB-53
trans-(+)-3,3',4',5,7-Flavanpentol
trans-(+)-3,3’,4’,5,7-Flavanpentol
trans3,3,4,5,7 Pentahydroxyflavane
YK-85 light yellow powder 85
Zyma
|
|
16 |
|
Tocopherol |
Approved, Investigational |
Phase 4 |
|
1406-66-2 |
|
Synonyms:
Methyltocols
tocoferol
tocoferoles
|
|
|
17 |
|
Zinc cation |
Approved, Experimental, Investigational |
Phase 4 |
|
7440-66-6, 23713-49-7 |
32051 |
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
Mannosidase b, alpha
Neutral alpha mannosidase
|
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc ion(2+)
Zinc(2+)
Zinc(II)
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
zinc|zinc ion
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
18 |
|
DL-alpha-Tocopherol |
Approved, Experimental, Investigational, Nutraceutical, Vet_approved |
Phase 4 |
|
59-02-9, 10191-41-0 |
2116 14985 |
Synonyms:
(-)-a-Tocopherol
(-)-Α-tocopherol
(+)-2R,4’R,8’R-α-Tocopherol
(+)-2R,4'R,8'R-alpha-Tocopherol
(+)-2R,4'R,8'R-α-Tocopherol
(+)-alpha-Tocopherol
(+)-a-Tocopherol
(+)-α-Tocopherol
(±)-α-tocopherol
(2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL
(2R)-3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol
(2R,4’R,8’R)-α-Tocopherol
(2R,4'R,8'R)-alpha-Tocopherol
(2R,4'r,8'r)-a-Tocopherol
(2R,4'R,8'R)-α-Tocopherol
(all-R)-alpha-Tocopherol
(all-R)-α-Tocopherol
(R,R,R)-alpha-Tocopherol
(R,R,R)-a-Tocopherol
(R,R,R)-α-Tocopherol
3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-(2R)-2H-1-benzopyran-6-ol
5,7,8-Trimethyltocol
a-D-Tocopherol
all-rac-alpha-tocopherol
Almefrol
ALPHA TOCOPHEROL
alpha-delta-Tocopherol
alpha-D-Tocopherol
alpha-Tocopherol
alpha-Vitamin E
Amino-Opti-E
AQUASOL E
a-Tocopherol
d-alpha-Tocopherol
Daltose
|
D-a-Tocopherol
delta-alpha-Tocopherol
Denamone
DL-5,7,8-trimethyltocol
DL-alpha tocopherol
DL-α-tocopherol
d-α-Tocopherol
E-200 I.U. Softgels
E307
E-Complex-600
E-Ferol
Emipherol
Eprolin
Etamican
E-VIMIN
E-Vitamin succinate
Evitaminum
Gordo-Vite E
NATOPHEROL
Phytogermin
Phytogermine
Profecundin
RRR-alpha-Tocopherol
RRR-alpha-Tocopheryl
TOCOPHEROL
Vitamin e
Vitamin E DL-alpha
Vitamin ea
Vitamin Ealpha
Vitamin Eα
Vitamin Plus E Softgells
Vitec
α-D-Tocopherol
α-Tocopherol
α-Vitamin E
|
|
19 |
|
Ascorbic acid |
Approved, Nutraceutical |
Phase 4 |
|
50-81-7 |
54676860 54670067 5785 |
Synonyms:
(+)-Ascorbate
(+)-Ascorbic acid
(+)-Sodium L-ascorbate
[<sup>14</sup>C]-ascorbic acid
3-keto-L-Gulofuranolactone
3-oxo-L-Gulofuranolactone
AA
Acid, ascorbic
Acid, L-ascorbic
Acide ascorbique
Acido ascorbico
ácido ascórbico
Acidum ascorbicum
Acidum ascorbinicum
Adenex
Allercorb
Antiscorbic vitamin
Antiscorbutic vitamin
arco-Cee
Ascoltin
ASCOR
Ascorb
Ascor-b.i.d.
Ascorbajen
Ascorbate
Ascorbate radical
Ascorbate, ferrous
Ascorbate, magnesium
Ascorbate, sodium
ASCORBIC ACID
Ascorbic acid radical
Ascorbic acid, monosodium salt
Ascorbicab
Ascorbicap
Ascorbicin
Ascorbin
Ascorbinsaeure
Ascorbinsäure
Ascorbutina
Ascorin
Ascorteal
Ascorvit
Cantan
Cantaxin
Catavin C
Ce lent
Cebicure
Cebid
Cebion
Cebione
Cecon
Cee-caps TD
Cee-vite
Cegiolan
Ceglion
Ceklin
Celaskon
Celin
Cell C
Cemagyl
Ce-mi-lin
Cemill
Cenetone
Cenolate
Cereon
Cergona
Cescorbat
Cetamid
Cetane
Cetane-caps TC
Cetane-caps TD
Cetebe
Cetemican
Cevalin
Cevatine
Cevex
Cevi-bid
Cevimin
Ce-vi-sol
Cevital
Cevitamate
Cevitamic acid
Cevitamin
Cevitan
Cevitex
Cewin
Chewcee
|
Ciamin
Cipca
Citriscorb
Citrovit
C-Level
C-Long
Colascor
Concemin
C-Quin
C-Span
C-Vimin
Davitamon C
Di-L-ascorbate, magnesium
Dora-C-500
Duoscorb
e 300
e300
e-300
Ferrous ascorbate
gamma-Lactone L-threo-hex-2-enonate
gamma-Lactone L-threo-hex-2-enonic acid
HiCee
Hybrin
ido-C
Juvamine
Kangbingfeng
Kyselina askorbova
L Ascorbic acid
L(+)-Ascorbate
L-(+)-Ascorbate
L(+)-Ascorbic acid
L-(+)-Ascorbic acid
L-3-Ketothreohexuronic acid lactone
Laroscorbine
L-Ascorbate
L-Ascorbic acid
Lemascorb
Liqui-cee
L-Lyxoascorbate
L-Lyxoascorbic acid
L-threo-Ascorbic acid
L-Xyloascorbate
L-Xyloascorbic acid
Magnesium ascorbate
Magnesium ascorbicum
Magnesium di L ascorbate
Magnesium di-L-ascorbate
Magnorbin
Meri-c
Monodehydroascorbate radical
Monodehydroascorbic acid radical
Natrascorb
Natrascorb injectable
Planavit C
Proscorbin
Redoxon
Ribena
Ronotec 100
Rontex 100
Roscorbic
Rovimix C
Scorbacid
Scorbu C
Scorbu-C
Secorbate
Semidehydroascorbate
Semidehydroascorbic acid
Sodascorbate
Sodium ascorbate
Suncoat VC 40
Testascorbic
VASC
Vicelat
Vicin
Vicomin C
Viforcit
Viscorin
Viscorin 100m
Vitace
Vitacee
Vitacimin
Vitacin
Vitamin C
Vitamina C
Vitamisin
Vitascorbol
Xitix
|
|
20 |
|
Lutein |
Approved, Investigational, Nutraceutical |
Phase 4 |
|
127-40-2 |
5281243 |
Synonyms:
(3R,3’R,6’R)-Lutein
(3R,3’R,6’R)-β,ε-Carotene-3,3’-diol
(3R,3'R,6'R)-beta,epsilon-Carotene-3,3'-diol
(3R,3'R,6'R)-Lutein
(3R,3'R,6'R)-β,ε-Carotene-3,3'-diol
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-b,b-carotene-3,3'-diol
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-BETA,BETA-carotene-3,3'-diol
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-β,β-carotene-3,3'-diol
(all-E)-Lutein
6’-Hydro-4’,5’-dehydro-β-carotene-3,3’-diol
6'-Hydro-4',5'-dehydro-beta-carotene-3,3'-diol
6'-Hydro-4',5'-dehydro-β-carotene-3,3'-diol
all-trans-(+)-Xanthophyll
all-trans-Lutein
all-trans-Xanthophyll
Bo-xan
E 161
|
e 161b
E161B
E-161B
E-161B(I)
gamma Lutein
INS NO.161B(I)
INS-161B(I)
Lutein
Lutein F
Lutein g
Lutein, gamma
Luteine
NSC-59193
trans-Lutein
Xanthophyll
Xantofyl
|
|
21 |
|
Cadexomer iodine |
Experimental |
Phase 4 |
|
94820-09-4 |
|
Synonyms:
|
22 |
|
Prednisolone hemisuccinate |
Experimental |
Phase 4 |
|
2920-86-7 |
4897 |
Synonyms:
(+)-prednisolone hemisuccinate
4-(2-{14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-3,6-dien-14-yl}-2-oxoethoxy)-4-oxobutanoate
Prednisolonbisuccinat
Prednisolone 21-hemisuccinate
Prednisolone 21-succinate
|
Prednisolone bisuccinate
PREDNISOLONE HEMISUCCINATE
Prednisolone hemisuccinic acid
Prednisolone hydrogen succinate
PREDNISOLONE SUCCINATE
|
|
23 |
|
Epicatechin |
Investigational |
Phase 4 |
|
490-46-0 |
58571364 72276 |
Synonyms:
(-)-Epicatechin
(-)-Epicatechol
(+)-Catechin
(+)-Cyanidanol
(+)-Cyanidanol-3
(2R,3R)-(-)-Epicatechin
3,3',4',5,7-Flavanpentol
3,3',4',5,7-Pentahydroxyflavane
Acid, catechinic
Acid, catechuic
alpha-Catechin
Catechin
Catechinic acid
Catechuic acid
Catergen
Cianidanol
Cyanidanol 3
|
Cyanidanol-3
EC
Epicatechin
Epi-catechin
Epicatechin-(2a->7,4a->8)-epicatechin 3-galactoside
Epicatechin-(2α->7,4α->8)-epicatechin 3-galactoside
Epicatechol
Epigallocatechin
KB 53
KB-53
L(-)-Epicatechin
L-Acacatechin
L-Epicatechin
L-Epicatechol
NSC-81161
Zyma
|
|
24 |
|
Theobromine |
Investigational |
Phase 4 |
|
83-67-0 |
5429 |
Synonyms:
2,6-Dihydroxy-3,7-dimethyl-purine
3,7-Dihydro-3,7-dimethyl-1H-purine-2,6-dione
3,7-DIMETHYL-2,3,6,7-TETRAHYDRO-1H-PURINE-2,6-DIONE
3,7-Dimethylpurine-2,6-dione
3,7-Dimethylxanthine
3,7-Dimethyl-xanthine
Diurobromine
FEMA NO. 3591
|
NSC-5039
SC-15090
Teobromin
Theobromin
THEOBROMINE
Théobromine
THEOBROMINE(20%)
|
|
25 |
|
Tocotrienol |
Investigational |
Phase 4 |
|
6829-55-6 |
9929901 |
Synonyms:
|
26 |
|
Lubricant Eye Drops |
|
Phase 4 |
|
|
|
27 |
|
Cathartics |
|
Phase 4 |
|
|
|
28 |
|
Carboxymethylcellulose Sodium |
|
Phase 4 |
|
|
|
29 |
|
Laxatives |
|
Phase 4 |
|
|
|
30 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
31 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
32 |
|
Cyclooxygenase Inhibitors |
|
Phase 4 |
|
|
|
33 |
|
Anesthetics |
|
Phase 4 |
|
|
|
34 |
|
Pyranoprofen |
|
Phase 4 |
|
|
|
35 |
|
Tocolytic Agents |
|
Phase 4 |
|
|
|
36 |
|
Anti-Anxiety Agents |
|
Phase 4 |
|
|
|
37 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
38 |
|
Hypnotics and Sedatives |
|
Phase 4 |
|
|
|
39 |
|
GABA Modulators |
|
Phase 4 |
|
|
|
40 |
|
Blood Substitutes |
|
Phase 4 |
|
|
|
41 |
|
Anti-Infective Agents, Local |
|
Phase 4 |
|
|
|
42 |
|
Disinfectants |
|
Phase 4 |
|
|
|
43 |
|
Plasma Substitutes |
|
Phase 4 |
|
|
|
44 |
|
Protective Agents |
|
Phase 4 |
|
|
|
45 |
|
Methylprednisolone Acetate |
|
Phase 4 |
|
|
584547 |
Synonyms:
Acetyl methylprednisolone
Acetyl-methylprednisolone
DEPMEDALONE
Depo medrol
Depo medrone
Depo-medrol
Depo-medrone
|
MEDROL ACETATE
Methylprednisolone 21 acetate
METHYLPREDNISOLONE ACETATE
Methylprednisolone acetate, (11beta,16alpha)-isomer
Methylprednisolone acetate, (11beta,16beta)-isomer
Methylprednisolone acetic acid
Methylprednisolone-21-acetate
|
|
46 |
|
Neuroprotective Agents |
|
Phase 4 |
|
|
|
47 |
|
Omega 3 Fatty Acid |
|
Phase 4 |
|
|
|
48 |
|
Vitamins |
|
Phase 4 |
|
|
|
49 |
|
Tocotrienols |
|
Phase 4 |
|
|
|
50 |
|
Tocopherols |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 1289)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A 7-month, Multicenter Study to Evaluate the Efficacy of Intravitreal Injections of Aflibercept (EYLEA) 2mg /0.05 ml as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration (NVAMD). |
Unknown status |
NCT01918878 |
Phase 4 |
Aflibercept (EYLEA) |
2 |
Multicenter Randomized Controlled Study of Intravitreal Ranibizumab and Triamcinolone Acetonide Combination Therapy Versus Ranibizumab Monotherapy in Patients With Polypoidal Choroidal Vasculopathy |
Unknown status |
NCT02806752 |
Phase 4 |
Triamcinolone Acetonide;Ranibizumab |
3 |
Random, Open-label Multicenter, Phase IV Study Assessing the Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD |
Unknown status |
NCT02810808 |
Phase 4 |
Ranibizumab |
4 |
Rationalization of the Systemic Treatment of Age-related Macular Degeneration With Rheohemapheresis (RHF) |
Unknown status |
NCT01943396 |
Phase 4 |
|
5 |
Treat and Extend Therapy Using Intravitreal Aflibercept (IAI) for Previously Treated Patients Exiting the Wet Age-related Macular Degeneration Extension Study (0910) |
Unknown status |
NCT01961414 |
Phase 4 |
Aflibercept |
6 |
Efficacy of Ranibizumab (Lucentis) in Combination With Photodynamic Therapy for Neovascular Age-Related Macular Degeneration |
Unknown status |
NCT00813891 |
Phase 4 |
Ranibizumab |
7 |
A Multicenter Study Comparing Efficacy and Safety of " Treat-and-Extend" Regimen Versus "Pro Re Nata" Regimen of Conbercept in Neovascular Age-related Macular Degeneration |
Unknown status |
NCT02802657 |
Phase 4 |
Conbercept |
8 |
A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement |
Unknown status |
NCT00354445 |
Phase 4 |
pegaptanib sodium (Macugen) |
9 |
Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept |
Unknown status |
NCT03468296 |
Phase 4 |
Intravitreal Aflibercept Injection 2mg |
10 |
Pharmacogenetics in Anti-VEGF Treatment Non-responders Suffering Exudative Age-related Macular Degeneration (AMD): Genetic Correlations and Intraocular Cytokine Concentrations |
Unknown status |
NCT01213667 |
Phase 4 |
Ranibizumab |
11 |
Intraocular Cytokine Changes in Recurrence of Polypoidal Choroidal Vasculopathy |
Unknown status |
NCT02976194 |
Phase 4 |
ranibizumab |
12 |
Pain Control Following Intravitreal Injection Using Topical Nepefanac 0.3% or Pressure Patching: A Prospective, Randomized, Placebo Controlled Trial |
Unknown status |
NCT03918590 |
Phase 4 |
nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX);Theratears tear drop, (Akron, Ann 111 Arbor, MI) |
13 |
On-label tReatment With Intravitreal Aflibercept Injection for Patients With Persistent Pigment Epithelial Detachments in Neovascular AMD. |
Unknown status |
NCT01670162 |
Phase 4 |
Aflibercept |
14 |
Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results |
Unknown status |
NCT01657669 |
Phase 4 |
Intravitreal Aflibercept injection |
15 |
Comparison of Early Intervention of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV Patients With Initial Loading Dose |
Unknown status |
NCT02864472 |
Phase 4 |
Ranibizumab;ranibizumab PRN |
16 |
A Randomized Control Trial of Intravitreal Ranibizumab (Lucentis) for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy for Choroidal Melanoma |
Unknown status |
NCT00540930 |
Phase 4 |
Ranibizumab |
17 |
Assessment in Early Changes in the Parameters of Optical Coherence Tomography (OCT Spectral Domain) in Patients With Subfoveal Neovascular Membranes Related to Age After Treatment With a Single Intravitreal Injection of Lucentis. |
Unknown status |
NCT01669447 |
Phase 4 |
|
18 |
Clinical and Genetic Assessment of Treatment Response in Patients With Age-related Macular Degeneration Using Intravitreal Aflibercept Injection |
Completed |
NCT02689518 |
Phase 4 |
Intravitreal aflibercept injection |
19 |
The IAI-OCTA Study or; Microvascular Structure and Morphology of Neovascular Membranes in Age Related Macular Degeneration (AMD) After Intravitreal Aflibercept Injection (IAI) Therapy Using OCT-Angiography Analysis |
Completed |
NCT03022292 |
Phase 4 |
Aflibercept Ophthalmic |
20 |
Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab |
Completed |
NCT02309281 |
Phase 4 |
aflibercept 2mg |
21 |
A Clinical Trial to Assess the Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Macular Degeneration (the LIBERTY Study). |
Completed |
NCT01863199 |
Phase 4 |
Lucentis (Treat and extend);Lucentis every 4 weeks;Lucentis every 12 weeks |
22 |
Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®) (2mg) Over a 12-week Period for Patients Suffering From Neovascular Age-related Macular Degeneration (AMD) French SD OCT in wAMD |
Completed |
NCT02246829 |
Phase 4 |
|
23 |
Phase IV Study to Evaluate the Efficacy of Aflibercept in Subjects With Neovascular Age-related Macular Degeneration (wAMD), Without Optimal Response to Repeated Monthly Intravitreal Injections of Anti Vascular Endothelial Growth Factor (Anti VEGF-A) Therapy. |
Completed |
NCT01896284 |
Phase 4 |
0.5mg aflibercept |
24 |
A Randomized, Open-label Phase 4 Study Evaluating the Efficacy and Safety of Repeated Doses of Intravitreal Aflibercept With Variable Treatment Intervals in Japanese Subjects With Neovascular Age-related Macular Degeneration |
Completed |
NCT02305238 |
Phase 4 |
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) |
25 |
A Randomised Controlled Trial of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration |
Completed |
NCT02060604 |
Phase 4 |
Ketorolac + Ranibizumab;Ranibizumab |
26 |
Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept in Patients With Exudative Age-related Macular Degeneration |
Completed |
NCT02125864 |
Phase 4 |
|
27 |
A Single Arm, Investigator Initiated Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Injection in Subjects With Exudative Age-related Macular Degeneration Previously Treated With Ranibizumab or Bevacizumab (ASSESS Study) |
Completed |
NCT01617148 |
Phase 4 |
Aflibercept |
28 |
Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration. |
Completed |
NCT02321839 |
Phase 4 |
Intraviteal Ranibizumab 0.5mg |
29 |
A Phase IV, Prospective, Open-label, Uncontrolled, European Study in Patients With Neovascular Age-related Macular Degeneration (nAMD), Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to Ranibizumab 0.5mg. |
Completed |
NCT02161575 |
Phase 4 |
Ranibizumab |
30 |
Correlation of Functional and Structural Outcomes With Serum Antibody Profiles in Patients With Neovascular Age-related Macular Degeneration Treated With Ranibizumab and Healthy Subjects: A Prospective, Controlled Monocenter Trial |
Completed |
NCT02843490 |
Phase 4 |
Ranibizumab |
31 |
Efficacy of Fixed Monthly Dosing of Lucentis® (Ranibizumab) on Subretinal Fluid (SRF) Associated With Persistent Pigment Epithelial Detachment (PED) in Neovascular Age-related Macular Degeneration (AMD): A Pilot Study |
Completed |
NCT02944227 |
Phase 4 |
Lucentis |
32 |
A 24-month, Randomized, Double-masked, Controlled, Multicenter Study Evaluating the Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With Neovascular Age Related Macular Degeneration (AMD) |
Completed |
NCT01775124 |
Phase 4 |
Ranibizumab |
33 |
FUSION Regimen: A Disease Activity Guided Treatment Algorithm With Ranibizumab in naïve Subjects With Exudative Age-related Macular Degeneration |
Completed |
NCT01500915 |
Phase 4 |
Ranibizumab |
34 |
A Phase IV, Long-term, Open-label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) |
Completed |
NCT00504959 |
Phase 4 |
ranibizumab |
35 |
A 12-month, Exploratory Open-label Study of Eylea (Aflibercept) in Subjects With Retinal Pigment Epithelial Detachment Secondary to Neovascular Age-related Macular Degeneration |
Completed |
NCT02142296 |
Phase 4 |
Eylea |
36 |
Development of New Geographic Atrophy in Patients With Neovascular (Wet) Age-related Macular Degeneration: a Comparison of Ranibizumab and Aflibercept |
Completed |
NCT02130024 |
Phase 4 |
Ranibizumab 0.5 mg;Aflibercept 2.0 mg |
37 |
Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration |
Completed |
NCT00556348 |
Phase 4 |
bevacizumab |
38 |
A Phase IV, Randomised, Single Masked Study Investigating the Efficacy and Safety of Ranibizumab "Inject and Extend" Using an Intensive Retinal Fluid Retreatment Regimen Compared to a Relaxed Retinal Fluid Retreatment Regimen in Patients With Wet Age-related Macular Degeneration (AMD) |
Completed |
NCT01972789 |
Phase 4 |
Ranibizumab |
39 |
A Randomized, Single-blinded, Multicenter, Phase IV Study to Compare Systemic VEGF Protein Dynamics Following Monthly Intravitreal Injections of 0.5 mg Ranibizumab Versus 2 mg Aflibercept Until Study Week 12 in Patients With Neovascular (Wet) Age-related Macular Degeneration |
Completed |
NCT02257632 |
Phase 4 |
Ranibizumab 0.5 mg;Aflibercept 2 mg |
40 |
Treatment of Exudative Age-Related Macular Degeneration With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3: A Randomized Trial |
Completed |
NCT03355638 |
Phase 4 |
Aflibercept Injection [Eylea];Pranoprofen Eyedrops;Omega-3 Supplementation |
41 |
A Prospective Pilot Study of Reduced Fluence Photodynamic Therapy With Visudyne® (Verteporfin) in Combination With Lucentis™ (Ranibizumab) for the Treatment of Age-Related Macular Degeneration |
Completed |
NCT00473642 |
Phase 4 |
Ranibizumab;Verteporfin |
42 |
A 3 Months, patient-and Rater Blinded, Randomized, Prospective Study Comparing Systemic Anti-VEGF Effects Between Ranibizumab and Aflibercept in Treatment naïve Neovascular Age-related Macular Degeneration (nAMD) Patients |
Completed |
NCT01988662 |
Phase 4 |
|
43 |
Efficacy of Ranibizumab Treatment Every 2 Month Compared to Treatment on Demand on Patients With Choroidal Neo-vascularization (CNV) as a Consequence of Age-related Macular Degeneration (AMD) |
Completed |
NCT01831947 |
Phase 4 |
|
44 |
Prospective, Randomized, Controlled Clinical Study Evaluating the Efficacy of Rheopheresis for Dry Age-Related Macular Degeneration Dry AMD Treatment With Rheopheresis Trial - ART |
Completed |
NCT00751361 |
Phase 4 |
|
45 |
A 12-month, Phase IV, Randomized, Open Label, Multicenter Study to Compare Efficacy of 0.5 mg Ranibizumab Pro re Nata (PRN) Versus 2 mg Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability Till Month 6 of Treatment and Explore Functional Outcomes up to Month 12 in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) |
Completed |
NCT01958918 |
Phase 4 |
Ranibizumab;Aflibercept |
46 |
Managing Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years With a Treat and Extend (T&E) Regimen of 2 mg Intravitreal Aflibercept - a Randomized, Open-label, Active-controlled, Parallel-group Phase IV/IIIb Study (ARIES) |
Completed |
NCT02581891 |
Phase 4 |
Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321) |
47 |
An Open-Label, Multicenter, Phase 4 Study of the Effect of Verteporfin for Injection Therapy in Subjects With Occult With No Classic Choroidal NeoVascularization Secondary to Age-Related Macular Degeneration |
Completed |
NCT00135837 |
Phase 4 |
Verteporfin for injection |
48 |
Time Course of Activity Signs at High Resolution OCT During OCT-guided High Frequency Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Age Related Macular Degeneration |
Completed |
NCT03393767 |
Phase 4 |
Ranibizumab |
49 |
Efficacy of Intravitreal Aflibercept Monotherapy for Submacular Hemorrhage Secondary to Neovascular Age-Related Macular Degeneration: A Prospective Clinical Trial |
Completed |
NCT03169660 |
Phase 4 |
Vascular endothelial growth factor trap-eye |
50 |
A Randomised Controlled Trial of Epimacular Brachytherapy Versus Ranibizumab Monotherapy for the Treatment of Subfoveal Choroidal Neovascularisation Associated With Wet Age-related Macular Degeneration in Patients Who Have Commenced Anti-VEGF Therapy |
Completed |
NCT01006538 |
Phase 4 |
Ranibizumab |
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
|
Interferons
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
|
Cell-based therapeutics:
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Macular Degeneration, Age-Related, 1:
Embryonic/Adult Cultured Cells Related to Macular Degeneration, Age-Related, 1:
|